Cell And Gene Therapy Manufacturing Market
Cell and Gene Therapy Manufacturing Market Forecasts to 2032 – Global Analysis By Therapy Type (Cell Therapy, Gene Therapy, Tissue-Engineered Products, Combination Regenerative Therapies and Other Therapy Types), Scale, Workflow, Mode, Technology, End User and By Geography
According to Stratistics MRC, the Global Cell and Gene Therapy Manufacturing Market is accounted for $6.004 billion in 2025 and is expected to reach $19.35 billion by 2032 growing at a CAGR of 18.2% during the forecast period. Cell and Gene Therapy (CGT) Manufacturing refers to the complex process of producing therapeutic products that involve modifying or using human cells or genetic material to treat diseases. It encompasses the sourcing of raw biological materials, cell isolation, genetic modification, expansion, purification, formulation, and quality control to ensure safety, efficacy, and consistency. Manufacturing can be autologous (patient-specific) or allogeneic (off-the-shelf) and often requires specialized facilities, advanced bioreactors, and strict regulatory compliance. CGT manufacturing integrates biotechnology, molecular biology, and engineering to create innovative therapies for conditions such as cancer, rare genetic disorders, and degenerative diseases.
Market Dynamics:
Driver:
Rising incidence of chronic and rare diseases
Conditions such as cancer hemophilia and neurodegenerative disorders require targeted and durable treatments that conventional drugs cannot address. Platforms support autologous and allogeneic cell processing viral vector production and ex vivo gene editing across therapeutic pipelines. Integration with personalized medicine and orphan drug programs enhances clinical relevance and regulatory alignment. Demand for curative and precision therapies is rising across aging populations and underserved disease areas. These dynamics are propelling infrastructure expansion and platform deployment across advanced therapy manufacturing ecosystems.
Restraint:
Supply chain and logistics issues
Cold chain requirements short shelf life and patient-specific workflows complicate transportation and inventory management. Raw material sourcing equipment availability and skilled labor shortages disrupt production timelines and quality assurance. Regulatory compliance across multi-site and cross-border operations adds to complexity and operational risk. Enterprises face challenges in aligning manufacturing with clinical demand and reimbursement cycles. These constraints continue to hinder platform maturity and global accessibility across cell and gene therapy programs.
Opportunity:
Increased investment in biopharmaceutical R&D
Governments venture capital and strategic partnerships are funding platform scale-up process optimization and regulatory engagement. Platforms support closed-system automation digital batch records and AI-driven quality control across upstream and downstream workflows. Demand for scalable and GMP-compliant manufacturing is rising across oncology rare diseases and regenerative medicine. Integration with CDMOs academic centers and hospital networks enhances flexibility and geographic reach. These trends are fostering growth across innovation-driven and investment-backed manufacturing ecosystems.
Threat:
Limited manufacturing infrastructure
Many regions lack GMP facilities trained personnel and validated equipment for high-volume and high-complexity therapies. Autologous workflows require decentralized and patient-specific setups that challenge traditional manufacturing models. CDMOs face bottlenecks in vector production cell expansion and release testing due to limited capacity and high demand. Regulatory delays and technology transfer issues further constrain scalability and commercialization. These limitations continue to restrict platform deployment across emerging markets and high-growth therapeutic areas.
Covid-19 Impact:
The pandemic disrupted supply chains clinical trials and facility operations across cell and gene therapy manufacturing. Lockdowns and resource reallocation delayed equipment delivery patient recruitment and regulatory review. However post-pandemic recovery emphasized resilience digitization and advanced therapy acceleration across healthcare systems. Investment in modular cleanrooms remote monitoring and decentralized manufacturing surged across biopharma and CDMO networks. Public awareness of genetic medicine and personalized therapies increased across consumer and clinical segments. These shifts are reinforcing long-term investment in cell and gene therapy infrastructure and global manufacturing capacity.
The viral vector platforms segment is expected to be the largest during the forecast period
The viral vector platforms segment is expected to account for the largest market share during the forecast period due to their foundational role in gene delivery across therapeutic applications. Platforms support AAV Lentivirus and retrovirus production for in vivo and ex vivo gene therapies. Integration with scalable upstream processing purification and analytics enhances yield potency and safety. Demand for high-performance and regulatory-grade vectors is rising across oncology ophthalmology and rare disease pipelines. Vendors offer modular platforms closed systems and digital QC tools to support GMP compliance and tech transfer. These capabilities are boosting segment dominance across gene therapy manufacturing workflows.
The commercial manufacturing segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the commercial manufacturing segment is predicted to witness the highest growth rate as cell and gene therapies transition from clinical trials to market authorization and global distribution. Platforms support scale-up batch release and regulatory documentation across approved and late-stage therapies. Integration with CDMOs hospital networks and logistics providers enhances throughput and geographic coverage. Demand for cost-efficient and compliant manufacturing is rising across CAR-T gene editing and regenerative medicine programs. Enterprises are aligning commercial readiness with payer engagement and post-market surveillance strategies.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share due to its advanced biopharma ecosystem regulatory engagement and infrastructure maturity across cell and gene therapy manufacturing. Enterprises and CDMOs deploy platforms across oncology rare disease and regenerative medicine programs with integrated analytics and automation. Investment in GMP facilities workforce development and digital manufacturing supports scalability and compliance. Presence of leading therapeutic developers academic centers and regulatory bodies drives innovation and standardization. Firms align manufacturing strategies with FDA guidance NIH funding and commercialization roadmaps.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare modernization biotech investment and disease burden converge across regional economies. Countries like China India Japan and South Korea scale manufacturing platforms across public health academic research and commercial therapy programs. Government-backed initiatives support infrastructure development CDMO expansion and international collaboration across advanced therapies. Local firms offer cost-effective and regionally adapted solutions tailored to regulatory frameworks and patient needs. These trends are accelerating regional growth across cell and gene therapy manufacturing innovation and deployment.
Key players in the market
Some of the key players in Cell and Gene Therapy Manufacturing Market include Thermo Fisher Scientific Inc., Lonza Group AG, Catalent Inc., Fujifilm Diosynth Biotechnologies Inc., WuXi Advanced Therapies Inc., Samsung Biologics Co., Ltd., AGC Biologics Inc., Minaris Regenerative Medicine GmbH, Oxford Biomedica plc, Charles River Laboratories International Inc., Recipharm AB, Merck KGaA, Takara Bio Inc., Miltenyi Biotec B.V. & Co. KG and BioNTech SE.
Key Developments:
In July 2025, Lonza confirmed that its $1.2 billion acquisition of Genentech’s Vacaville facility (2024) drove CHF 3.1 billion in H1 2025 CDMO sales, with 23.1% growth at constant exchange rates. The 330,000-liter bioreactor site significantly boosted Lonza’s biologics capacity and margin resilience, outperforming peers like WuXi and Samsung. This acquisition positioned Lonza as a global CDMO leader in large-scale cell and gene therapy manufacturing.
In April 2025, Thermo Fisher launched Gibco™ CTS Viral Vector Production System, a closed modular solution for AAV and lentiviral manufacturing. The system enabled scalable, GMP-compliant production for clinical and commercial gene therapies. It integrated with Thermo’s bioprocessing and analytics platforms, supporting faster turnaround and reduced contamination risk in cell and gene therapy workflows.
Therapy Types Covered:
• Cell Therapy
• Gene Therapy
• Tissue-Engineered Products
• Combination Regenerative Therapies
• Other Therapy Types
Scales Covered:
• Research & Development
• Clinical-Scale Manufacturing
• Commercial Manufacturing
Workflows Covered:
• Vector Production
• Cell Processing
• Cell Banking
• Regulatory Compliance & Validation
• Other Workflows
Modes Covered:
• In-House Manufacturing
• Contract Manufacturing (CDMOs)
• Hybrid Manufacturing Models
Technologies Covered:
• Viral Vector Platforms
• Non-Viral Delivery Systems
• Cell Expansion & Banking Technologies
• Quality Control & Release Testing Tools
• Other Technologies
End Users Covered:
• Biopharmaceutical Companies
• Academic & Research Institutes
• CROs & CDMOs
• Hospitals & Clinics
• Cell & Gene Therapy Startups
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Cell and Gene Therapy Manufacturing Market, By Therapy Type
5.1 Introduction
5.2 Cell Therapy
5.3 Gene Therapy
5.4 Tissue-Engineered Products
5.5 Combination Regenerative Therapies
5.6 Other Therapy Types
6 Global Cell and Gene Therapy Manufacturing Market, By Scale
6.1 Introduction
6.2 Research & Development
6.3 Clinical-Scale Manufacturing
6.4 Commercial Manufacturing
7 Global Cell and Gene Therapy Manufacturing Market, By Workflow
7.1 Introduction
7.2 Vector Production
7.3 Cell Processing
7.4 Cell Banking
7.5 Regulatory Compliance & Validation
7.6 Other Workflows
8 Global Cell and Gene Therapy Manufacturing Market, By Mode
8.1 Introduction
8.2 In-House Manufacturing
8.3 Contract Manufacturing (CDMOs)
8.4 Hybrid Manufacturing Models
9 Global Cell and Gene Therapy Manufacturing Market, By Technology
9.1 Introduction
9.2 Viral Vector Platforms
9.3 Non-Viral Delivery Systems
9.4 Cell Expansion & Banking Technologies
9.5 Quality Control & Release Testing Tools
9.6 Other Technologies
10 Global Cell and Gene Therapy Manufacturing Market, By End User
10.1 Introduction
10.2 Biopharmaceutical Companies
10.3 Academic & Research Institutes
10.4 CROs & CDMOs
10.5 Hospitals & Clinics
10.6 Cell & Gene Therapy Startups
10.7 Other End Users
11 Global Cell and Gene Therapy Manufacturing Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 Thermo Fisher Scientific Inc.
13.2 Lonza Group AG
13.3 Catalent Inc.
13.4 Fujifilm Diosynth Biotechnologies Inc.
13.5 WuXi Advanced Therapies Inc.
13.6 Samsung Biologics Co., Ltd.
13.7 AGC Biologics Inc.
13.8 Minaris Regenerative Medicine GmbH
13.9 Oxford Biomedica plc
13.10 Charles River Laboratories International Inc.
13.11 Recipharm AB
13.12 Merck KGaA
13.13 Takara Bio Inc.
13.14 Miltenyi Biotec B.V. & Co. KG
13.15 BioNTech SE
List of Tables
1 Global Cell and Gene Therapy Manufacturing Market Outlook, By Region (2024-2032) ($MN)
2 Global Cell and Gene Therapy Manufacturing Market Outlook, By Therapy Type (2024-2032) ($MN)
3 Global Cell and Gene Therapy Manufacturing Market Outlook, By Cell Therapy (2024-2032) ($MN)
4 Global Cell and Gene Therapy Manufacturing Market Outlook, By Gene Therapy (2024-2032) ($MN)
5 Global Cell and Gene Therapy Manufacturing Market Outlook, By Tissue-Engineered Products (2024-2032) ($MN)
6 Global Cell and Gene Therapy Manufacturing Market Outlook, By Combination Regenerative Therapies (2024-2032) ($MN)
7 Global Cell and Gene Therapy Manufacturing Market Outlook, By Other Therapy Types (2024-2032) ($MN)
8 Global Cell and Gene Therapy Manufacturing Market Outlook, By Scale (2024-2032) ($MN)
9 Global Cell and Gene Therapy Manufacturing Market Outlook, By Research & Development (2024-2032) ($MN)
10 Global Cell and Gene Therapy Manufacturing Market Outlook, By Clinical-Scale Manufacturing (2024-2032) ($MN)
11 Global Cell and Gene Therapy Manufacturing Market Outlook, By Commercial Manufacturing (2024-2032) ($MN)
12 Global Cell and Gene Therapy Manufacturing Market Outlook, By Workflow (2024-2032) ($MN)
13 Global Cell and Gene Therapy Manufacturing Market Outlook, By Vector Production (2024-2032) ($MN)
14 Global Cell and Gene Therapy Manufacturing Market Outlook, By Cell Processing (2024-2032) ($MN)
15 Global Cell and Gene Therapy Manufacturing Market Outlook, By Cell Banking (2024-2032) ($MN)
16 Global Cell and Gene Therapy Manufacturing Market Outlook, By Regulatory Compliance & Validation (2024-2032) ($MN)
17 Global Cell and Gene Therapy Manufacturing Market Outlook, By Other Workflows (2024-2032) ($MN)
18 Global Cell and Gene Therapy Manufacturing Market Outlook, By Mode (2024-2032) ($MN)
19 Global Cell and Gene Therapy Manufacturing Market Outlook, By In-House Manufacturing (2024-2032) ($MN)
20 Global Cell and Gene Therapy Manufacturing Market Outlook, By Contract Manufacturing (CDMOs) (2024-2032) ($MN)
21 Global Cell and Gene Therapy Manufacturing Market Outlook, By Hybrid Manufacturing Models (2024-2032) ($MN)
22 Global Cell and Gene Therapy Manufacturing Market Outlook, By Technology (2024-2032) ($MN)
23 Global Cell and Gene Therapy Manufacturing Market Outlook, By Viral Vector Platforms (2024-2032) ($MN)
24 Global Cell and Gene Therapy Manufacturing Market Outlook, By Non-Viral Delivery Systems (2024-2032) ($MN)
25 Global Cell and Gene Therapy Manufacturing Market Outlook, By Cell Expansion & Banking Technologies (2024-2032) ($MN)
26 Global Cell and Gene Therapy Manufacturing Market Outlook, By Quality Control & Release Testing Tools (2024-2032) ($MN)
27 Global Cell and Gene Therapy Manufacturing Market Outlook, By Other Technologies (2024-2032) ($MN)
28 Global Cell and Gene Therapy Manufacturing Market Outlook, By End User (2024-2032) ($MN)
29 Global Cell and Gene Therapy Manufacturing Market Outlook, By Biopharmaceutical Companies (2024-2032) ($MN)
30 Global Cell and Gene Therapy Manufacturing Market Outlook, By Academic & Research Institutes (2024-2032) ($MN)
31 Global Cell and Gene Therapy Manufacturing Market Outlook, By CROs & CDMOs (2024-2032) ($MN)
32 Global Cell and Gene Therapy Manufacturing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
33 Global Cell and Gene Therapy Manufacturing Market Outlook, By Cell & Gene Therapy Startups (2024-2032) ($MN)
34 Global Cell and Gene Therapy Manufacturing Market Outlook, By Other End Users (2024-2032) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
